After 33 years of leadership and service to the company, Johnson & Johnson Executive Vice President and General Counsel Michael Ullmann will retire from his position at the end of this year according to a Monday announcement.
Ullmann will be succeeded in the role by Elizabeth Forminard, a Credo-based leader who has had an exceptional career with depth and breadth across the company’s Pharmaceutical, MedTech and Consumer Health sectors. Forminard will also be appointed as a member of Johnson & Johnson’s Executive Committee, effective Oct. 17.
Ullmann and Forminard will work together during a transition period until Ullmann’s retirement at the end of this year.
“For three decades, Mike set the standard for Credo leadership at the company. I thank him for his unwavering commitment to help deliver on our purpose of advancing health for humanity,” Joaquin Duato, CEO, Johnson & Johnson stated. “Throughout his tenure, Mike has guided the company through an evolving global environment with respect and clarity, always keeping our patients and customers at the center of all decisions.”
Ullmann joined Johnson & Johnson as a mergers & acquisitions attorney in 1989 and has since held positions of increasing responsibility in the company’s Law Department, ultimately serving as general counsel for the past 11 years.
During his time with the company, Ullmann has led it through complex matters while ensuring all company standards and policies reflect the needs of a changing world and a new generation of employees. A dedicated advocate for diversity, equity & inclusion, he has also served as the executive sponsor for the company’s Hispanic and Latino employee resource group and as a member of the Leadership Council on Legal Diversity, an organization that works to build a more open and diverse legal profession.
Forminard has been with Johnson & Johnson for 16 years, having served as general counsel across each of the Pharmaceutical, Consumer Health and MedTech sectors, as well as worldwide vice president leading the corporate governance function, and numerous other functional and business-facing roles during this time.
In her most recent role, Forminard served as general counsel for the Pharmaceuticals Legal Group and member of the Pharmaceuticals Group Operating Committee, leading the legal function globally for the sector and for Johnson & Johnson Global External Innovation and Global Public Health, where she drove programs to ensure optimal, aligned intellectual property, regulatory and commercial strategies internally, and helped to shape the global health care environment externally.
